Herriot Tabuteau sold $22M of AXSM
Chief Executive Officer at Axsome Therapeutics, Inc.. 163,939 shares at an average of $133.07, traded Nov 3, 2025, filed Nov 5, 2025.
Score components
- +25RoleCEO
- +25Trade size$21.8M at market
- +20Share of holdings soldSold 100% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-25-267467, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 3, 2025 | MOption exercise Common Stock10b5-1 | +91,705 | $8.02 | $735k | 98,934 | Nov 5, 2025 |
| Nov 3, 2025 | SOpen-market sale Common Stock10b5-1 | -91,705 | $132.34 | $12M | 7,229 | Nov 5, 2025 |
| Nov 4, 2025 | MOption exercise Common Stock10b5-1 | +50,459 | $8.02 | $405k | 57,688 | Nov 5, 2025 |
| Nov 4, 2025 | SOpen-market sale Common Stock10b5-1 | -50,459 | $133.79 | $6.8M | 7,229 | Nov 5, 2025 |
| Nov 5, 2025 | MOption exercise Common Stock10b5-1 | +21,775 | $8.02 | $175k | 29,004 | Nov 5, 2025 |
| Nov 5, 2025 | SOpen-market sale Common Stock10b5-1 | -21,775 | $134.49 | $2.9M | 7,229 | Nov 5, 2025 |
| Nov 3, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -91,705 | $0.00 | $0 | 324,031 | Nov 5, 2025 |
| Nov 4, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -50,459 | $0.00 | $0 | 273,572 | Nov 5, 2025 |
| Nov 5, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -21,775 | $0.00 | $0 | 251,797 | Nov 5, 2025 |
Related signals
Other insiders at Axsome Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | Axsome Therapeutics, Inc. | Mark L. Jacobson Chief Operating Officer | $2.1M 10,000 shares | -100% | |
| 38Weak | Axsome Therapeutics, Inc. | Mark L. Jacobson Chief Operating Officer | $5.7M 35,378 shares | -100% | |
| 38Weak | Axsome Therapeutics, Inc. | Mark Coleman director | $4.0M 25,000 shares | -35% | |
| 50Moderate | Axsome Therapeutics, Inc. | Herriot Tabuteau Chief Executive Officer | $6.0M 32,410 shares | -82% | |
| 40Moderate | Axsome Therapeutics, Inc. | Ari Maizel Chief Commercial Officer | $1.4M 7,500 shares | -100% | |
| 32Weak | Axsome Therapeutics, Inc. | Nick Pizzie Chief Financial Officer | $2.3M 12,000 shares | -22% | |
| 43Moderate | Axsome Therapeutics, Inc. | Herriot Tabuteau Chief Executive Officer | $24M 139,414 shares | -162% | |
| 33Weak | Axsome Therapeutics, Inc. | Mark E Saad director | $6.2M 37,577 shares | -231% | |
| 35Weak | Axsome Therapeutics, Inc. | Herriot Tabuteau Chief Executive Officer | $12M 79,973 shares | -142% | |
| 43Moderate | Axsome Therapeutics, Inc. | Herriot Tabuteau Chief Executive Officer | $5.4M 45,384 shares | -172% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.